CommercialBilling CodesHigh impact
08.01.90d, Amivantamab-vmjw (Rybrevant®) and Amivantamab and hyaluronidase-lpuj (Rybrevant Faspro™)
Independence Blue Cross·Oncology, Pharmacy·Pharmacy
Effective date
Jul 1, 2026
We identified it
Jul 2, 2026
Summary
Effective 07/01/2026, Independence Blue Cross is replacing two unclassified NOC/HCPCS codes (C9399 and J3590) with a single specific HCPCS code J9062 for Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) subcutaneous injections. Billing teams must update systems to discontinue use of the old codes and transition all claims for this drug to the new J9062 code to avoid claim rejections.
Action Required
By 06/30/2026: Billing team must update all billing software and claims submission systems to REMOVE codes C9399 and J3590 from use for Rybrevant Faspro claims. Replace with HCPCS code J9062 (Injection, amivantamab 5 mg and hyaluronidase-lpuj). Update all charge masters, billing templates, and superbill configurations to reflect this change. Communicate transition to providers and clinical staff. Effective 07/01/2026, all claims submitted with C9399 or J3590 for this drug will likely be denied. Verify the change is live in the system before the effective date. Retain J9061 for IV formulation (Rybrevant) which remains unchanged.